Skip to contentZ
Zivo Bioscience, Inc.
Z
ZIVOZivo Bioscience, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$11.80K$11.80Kderived— vs Q4 2022 Net Income-$1.91M-$1.91MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Zivo Bioscience, Inc. · CIK 1101026 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$4,131— Operating Incomederived-$1,896,584N/M Operating Cash Flowderived-$715,733N/M Margins · derivedGross margin35.0%
Operating margin-16072.7%
Net margin-16174.1%
ended Dec 31, 2023 · filed Mar 15, 2024 · 75 d after period end